31 Oct 2016 07:00
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
This announcement contains inside information.
Motif Bio plc
("Motif Bio" or the "Company")
New data on iclaprim released at IDWeek 2016
Iclaprim shown to be highly potent against SSSI and HABP clinical isolates
Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that new data were presented on the antimicrobial activity of its lead antibiotic, iclaprim, against recent clinical samples of Gram-positive bacteria, including multidrug resistant isolates, gathered from around the World.
The new data were presented during IDWeek 2016 in New Orleans and provided details of a global in vitro microbiological surveillance programme testing 1636 strains of bacteria associated with Hospital Associated Bacterial Pneumonia ("HABP") and Skin and Skin Structure Infections ("SSSI") collected from patients in the United States, Europe, Latin America and the Asia Pacific. These bacteria were tested against iclaprim and a range of other standard of care antibiotics.
As demonstrated in the Table below, the results showed that iclaprim was highly potent against strains of Staphylococcus aureus, beta-hemolytic streptococci, and Streptococcus pneumoniae associated with clinical SSSI and HABP isolates taken globally during 2012 to 2014.
(MIC50/90 mg/L) | |||||
Pathogen | n | Iclaprim | Vancomycin | Linezolid | Daptomycin |
Staphylococcus aureus | 1,178 | 0.06/0.12 | 1/1 | 1/1 | 0.25/0.5 |
MRSA | 582 | 0.06/0.5 | 1/1 | 1/1 | 0.25/0.5 |
MSSA | 596 | 0.06/0.12 | 1/1 | 1/1 | 0.25/0.5 |
Beta-hemolytic streptococci | 199 | 0.06/0.25 | 0.25/0.5 | 1/1 | 0.12/0.25 |
Streptococcus pneumoniae | 259 | 0.06/2 | 0.25/0.5 | 1/1 | 0.12/0.25 |
Total | 1636 | ||||
The full poster can be down loaded at:
https://idsa.confex.com/idsa/2016/webprogram/Paper56742.html
A registration statement relating to the Company's securities has been filed with the SEC, but has not yet become effective. Such securities may not be sold, nor may offers to buy the securities be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
For further information please contact:
Motif Bio plc Richard Morgan (Chairman) Graham Lumsden (Chief Executive Officer)
| info@motifbio.com
|
Zeus Capital Limited (NOMAD & BROKER) Phil Walker/Giles Balleny Dominic Wilson
| +44 (0)20 3829 5000 |
Northland Capital Partners Limited (BROKER) Patrick Claridge/ David Hignell John Howes/ Rob Rees (Broking)
| +44 (0)20 3861 6625 |
Walbrook PR Ltd. (FINANCIAL PR & IR) Paul McManus Mike Wort | +44 (0)20 7933 8780 or motifbio@walbrookpr.com Mob: +44 (0)7980 541 893 Mob: +44 (0)7900 608 002 |
MC Services AG (EUROPEAN IR) | |
Raimund Gabriel | +49 (0)89 210 2280 |
About Motif Bio
Motif Bio is a clinical-stage biopharmaceutical company, engaged in the research and development of novel antibiotics designed to be effective against serious and life-threatening infections in hospitalized patients caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including ventilator associated bacterial pneumonia (VABP), which is often caused by MRSA (methicillin resistant Staphylococcus aureus). We are currently enrolling and dosing patients in two global Phase 3 clinical trials (Revive 1 and Revive 2) with an intravenous formulation of iclaprim, for the treatment of ABSSSI. Patient enrolment for REVIVE-1 has exceeded projections and data readout is now expected in the second quarter of 2017, rather than the second half of 2017, as previously stated. REVIVE-2 remains on track with data readout continuing to be expected in the second half of 2017.